leadXpro and Paul Scherrer Institute sign agreement on Beam Line at the Swiss Light Source

Villigen, CH, 14th of December 2016– Paul Scherrer Institute (“PSI”), an institute of the ETH domain, and leadXpro AG (“leadXpro”), a company dedicated to structure based drug discovery on membrane proteins, announce an agreement on the use, maintenance and operation of the X10SA-PXII protein crystallography beamline for proprietary research.

In the collaboration, leadXpro will join the consortium of Novartis (CH), Roche (CH) and the Max-Planck-Gesellschaft (MPG, D) to become a beamline partner and share the operation and beamtime. This engagement brings guaranteed access to this facility for the next 10 years. Michael Hennig, Chief Executive Officer of leadXpro said: “While we are looking forward to the first experiments at the Swiss Free Electron Laser (SwissFEL), we are convinced that measurements at the synchrotron source will remain an essential part of X-ray data collection strategy of leadXpro.”

Oliver Bunk, head of the laboratory for macromolecules and bio-imaging, said: “This long-term commitment is an excellent framework for providing state-of-the-art macromolecular crystallography services while pushing the frontiers in methods and instrumentation for this rapidly developing field. ”


About Paul Scherrer Institute

The Paul Scherrer Institute PSI develops, builds and operates large, complex research facilities and makes them available to the national and international research community. The institutes own key research priorities are in the fields of matter and materials, energy and environment and human health. PSI is committed to the training of future generations. Therefore, about one quarter of its staff are post-docs, post-graduates or apprentices. Altogether PSI employs 2000 people, thus being the largest research institute in Switzerland. The annual budget amounts to approximately CHF 370 million. PSI is part of the ETH Domain, with the other members being the two Swiss Federal Institutes of Technology, ETH Zurich and EPFL Lausanne, as well as Eawag (Swiss Federal Institute of Aquatic Science and Technology), Empa (Swiss Federal Laboratories for Materials Science and Technology) and WSL (Swiss Federal Institute for Forest, Snow and Landscape Research).


About leadXpro AG

leadXpro is a lead discovery company focusing on membrane protein drug targets. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds. leadXpro’s technology platform enables structural determination of membrane proteins where classical crystallographic techniques fail, unlocking structure-based drug discovery for challenging targets. We capitalize on the knowledge regarding membrane protein structural biology and facilities of the Paul Scherrer Institute (PSI) with premium access to the synchrotron Swiss Light Source (SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray include single particle cryo-electron microscopy (cryo-EM) and electron diffraction (ED). For more information, please visit www.leadxpro.com

leadXpro is a registered trademark in the EU, Switzerland, US and Canada.


Contact Information

Paul Scherrer Institute
leadXpro AG
Oliver Bunk (Oliver.Bunk at psi.ch)
Michael Hennig, CEO (michael.hennig at leadXpro.com)

Text content